Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Access Pharmaceuticals Announces Publication Of Thiarabine Combination Data
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced that new Thiarabine preclinical efficacy data will shortly be published demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agent alone. In one colorectal cancer model, 66% of mice were cured of their tumors. The publication which will appear in the journal "Cancer Chemotherapy and Pharmacology," was based on work conducted by Access" collaborators at the Southern Research Institute. The paper is entitled "Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine" (thiarabine).
generic viagra online
New Data Show Cost Savings Achieved By Treating Mild And Moderate Alzheimer's Patients With Aricept(R)
Researchers attending the annual meeting of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR), heard today that prescribing Aricept® (donepezil hydrochloride) as soon as patients are diagnosed with either mild or moderate Alzheimer"s disease saves the NHS money. The findings contradict the recommendation by NICE that these medicines are not cost effective in the early stages of the disease, a decision that has been the subject of much recent debate. Drugshop to buy zoloft online and other pills.
News of the day
UC Davis Researchers Visualize Formation Of A New Synapse
A protein called neuroligin that is implicated in some forms of autism is critical to the construction of a working synapse, locking neurons together like "molecular Velcro," a study lead by a team of UC Davis researchers has found.
Diagnostics

National Pharmacy Association Calls For Zero Increase In RPSGB Retention Fees - UK

The NPA is asking for the RPSGB retention fee to be held at the present level, given the financial pressures on pharmacy businesses, many of which pay retention fees for their staff. Margaret Peycke, NPA External Relations Manager said: "The justification to charge RPSGB members more is unclear, especially as such a large increase in fees (40%) was made in 2008, the declared purpose of which was to provide the RPSGB with the res to create the regulatory and professional leadership bodies. In such circumstances, an uplift to fees in the region of 2.2% is inappropriate." "NPA members already coping with a challenging economic environment are not in a position to comfortably absorb such increases, bearing in mind that many employers fund their employee pharmacist and technician retention fees. The NPA has recently surveyed its members and over 80% highlighted the current burden of costs on their pharmacy business." In addition the fee set by the RPSGB is a fee which will be divided between the new regulatory body (GPhC) and the new professional leadership body (PLB) after the split which is due to occur in April 2010. The document does not indicate how the fees will be apportioned between the bodies or make mention of the fact that existing members of RPSGB who do not wish to join the new PLB do not have to and will be entitled to a refund on the unused element of the fees apportioned to the PLB. National Pharmacy Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009